VBL Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update
16 nov. 2020 07h00 HE
|
VBL Therapeutics
- Continued progress in OVAL Phase 3 potential-registration study in patients with platinum-resistant ovarian cancer; high response rates (RR) of over 50% in the total evaluable patient population...
VBL Therapeutics to Present at the H.C. Wainwright 6th Annual Israel Conference
05 nov. 2020 07h00 HE
|
VBL Therapeutics
TEL AVIV, Israel, Nov. 05, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...
VBL Therapeutics to Report Third Quarter 2020 Financial Results on November 16
02 nov. 2020 07h00 HE
|
VBL Therapeutics
TEL AVIV, Israel, Nov. 02, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...
VBL Therapeutics Announces Additional New European Patent in the MOSPD2 Platform Technology, This Time for Treatment of Cancer
15 oct. 2020 07h00 HE
|
VBL Therapeutics
TEL AVIV, Israel, Oct. 15, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), today announced that the European Patent Office (EPO) has granted Patent #3328401, which covers VBL’s proprietary...
VBL Therapeutics Announces Appointment of Marc Kozin as Vice Chairman of Board of Directors
13 oct. 2020 07h00 HE
|
VBL Therapeutics
TEL AVIV, Israel, Oct. 13, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced that it has appointed Marc Kozin as Vice Chairman of the Board. Mr. Kozin will transition to...
Newly Granted European Patent Protects VBL Therapeutics' Anti-MOSPD2 Antibodies for Inflammation Until at least July 2036
12 oct. 2020 07h00 HE
|
VBL Therapeutics
TEL AVIV, Israel, Oct. 12, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), today announced that the European Patent Office (EPO) has granted Patent #3328408, which covers VBL’s proprietary...
VBL Therapeutics to Present at the Chardan 4th Annual Genetic Medicines Conference
29 sept. 2020 08h00 HE
|
VBL Therapeutics
TEL AVIV, Israel, Sept. 29, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...
VBL Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
21 sept. 2020 16h01 HE
|
VBL Therapeutics
TEL AVIV, Israel, Sept. 21, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...
VBL Therapeutics to Provide an Update on the OVAL Study Today at the H. C. Wainwright 22nd Annual Global Investment Conference
15 sept. 2020 08h00 HE
|
VBL Therapeutics
TEL AVIV, Israel, Sept. 15, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) will present today a corporate overview, including an update on the OVAL pivotal study, at the H. C. Wainwright...
VBL Presents Human Proof-of-Concept Data That Show the Potential of its Novel anti-MOSPD2 Monoclonal Antibodies for Multiple Sclerosis at the MS Virtual 2020 Meeting
11 sept. 2020 08h00 HE
|
VBL Therapeutics
TEL AVIV, Israel, Sept. 11, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), today presents for the first time new data demonstrating ex-vivo activity of its proprietary investigational...